Immunohistochemistry Was Performed For IDH, ATRX, P53, MIB, HIP 1 R, Vimentin, and H3K27me3 on Tumor Samples From Oligodendroglioma (Grades 2 and 3), Astrocytoma (Grades 2, 3, and 4), and Glioblastoma.
| Tumors . | n . | IDH R 132 H . | ATRX . | P53 . | Hip1R . | Vimentin . | H3K27Me3 . | 1p/19q co-deletion (FISH assay) . | Mean survival . |
|---|---|---|---|---|---|---|---|---|---|
| Oligodendroglioma (ODG) Validating Cohort | 102 24 | +ve (IHC): 97 (98.5%) +ve (SS): 5 (1.5%) +ve (IHC): 23 (95.8%) +ve (SS): 1 (4.2%) | Retained: 102 (100%) Retained: 24 (100%) | −ve: 102 (100%) −ve: 24 (100%) | H: 86 (84.3%) H + M: 16 (15.7%) H: 21 (87.5%) H + M: 3 (12.5%) | −ve: 93 (91.2%) FP: 9 (8.8%) −ve: 18 (75%) FP: 6 (25%) | CL: 102 (100%) CL: 23 (95.8%) PL: 1 (4.2%) | All cases All Cases | 21.23 months (range: 1.2–103.4 months) |
| Astrocytoma Validating Cohort | 44 22 | +ve (IHC): 40 (90.9%) +ve (SS): 4 (9.1%) +ve (IHC): 24 (100%) | Loss: 34 (77.3%) Retained: 10 (22.7%) Loss: 19 (86.4%) Retained: 3 (13.6%) | +ve: 33 (75%) −ve: 11 (25%) +ve: 21 (95.5%) −ve: 1 (4.5%) | M: 36 (81.8%) Sparse: 5 (11.4%) −ve: 3 (6.8%) M: 17 (77.2%) Sparse: 1 (4.5%) −ve: 4 (18.3%) | DP: 36 (81.8%) FP: 8 (18.2%) DP: 19 (86.4%) FP: 3 (13.6%) | CL: 33 (75%) PL: 9 (20.5%) Retained: 2 (4.5%) CL: 11 (50%) PL: 11 (50%) | None None | 18.25 months (range: 2–81.4 months) |
| GBM Validating Cohort | 36 27 | −ve: 36(100%) −ve: 27 (100%) | Retained: 36 (100%) Retained: 27 (100%) | +ve: 10 (27.7%)−ve: 26 (72.3%) +ve: 6 (22.2%) −ve: 21 (77.8%) | M: 28 (77.8%) H + M: 2 (5.6%) Sparse: 3 (8.3%) −ve: 3 (8.3%) M: 19 (70.4%) H + M: 1 (3.7%) Sparse: 3 (11.1%) −ve: 4 (14.8%) | DP: 25 (69.4%) FP: 11 (30.6%) DP: 17 (62.9%) FP: 9 (33.3%) −ve: 1 (3.7%) | PL: 19 (52.7%) CL: 10 (27.7%) Retained: 7 (19.6%) PL: 12 (44.4%) CL: 9 (33.3%) Retained: 6 (22.3%) | None None | 10.93 months (range: 0.2–82.6 months) |
| P value ODG vs Astro ODG vs GBM | – | 0.19 <0.001 | <0.001 0.17 | <0.001 0.20 | <0.001 0.02 | <0.05 0.045 | 0.15 0.007 | – | <0.001 |
| Tumors . | n . | IDH R 132 H . | ATRX . | P53 . | Hip1R . | Vimentin . | H3K27Me3 . | 1p/19q co-deletion (FISH assay) . | Mean survival . |
|---|---|---|---|---|---|---|---|---|---|
| Oligodendroglioma (ODG) Validating Cohort | 102 24 | +ve (IHC): 97 (98.5%) +ve (SS): 5 (1.5%) +ve (IHC): 23 (95.8%) +ve (SS): 1 (4.2%) | Retained: 102 (100%) Retained: 24 (100%) | −ve: 102 (100%) −ve: 24 (100%) | H: 86 (84.3%) H + M: 16 (15.7%) H: 21 (87.5%) H + M: 3 (12.5%) | −ve: 93 (91.2%) FP: 9 (8.8%) −ve: 18 (75%) FP: 6 (25%) | CL: 102 (100%) CL: 23 (95.8%) PL: 1 (4.2%) | All cases All Cases | 21.23 months (range: 1.2–103.4 months) |
| Astrocytoma Validating Cohort | 44 22 | +ve (IHC): 40 (90.9%) +ve (SS): 4 (9.1%) +ve (IHC): 24 (100%) | Loss: 34 (77.3%) Retained: 10 (22.7%) Loss: 19 (86.4%) Retained: 3 (13.6%) | +ve: 33 (75%) −ve: 11 (25%) +ve: 21 (95.5%) −ve: 1 (4.5%) | M: 36 (81.8%) Sparse: 5 (11.4%) −ve: 3 (6.8%) M: 17 (77.2%) Sparse: 1 (4.5%) −ve: 4 (18.3%) | DP: 36 (81.8%) FP: 8 (18.2%) DP: 19 (86.4%) FP: 3 (13.6%) | CL: 33 (75%) PL: 9 (20.5%) Retained: 2 (4.5%) CL: 11 (50%) PL: 11 (50%) | None None | 18.25 months (range: 2–81.4 months) |
| GBM Validating Cohort | 36 27 | −ve: 36(100%) −ve: 27 (100%) | Retained: 36 (100%) Retained: 27 (100%) | +ve: 10 (27.7%)−ve: 26 (72.3%) +ve: 6 (22.2%) −ve: 21 (77.8%) | M: 28 (77.8%) H + M: 2 (5.6%) Sparse: 3 (8.3%) −ve: 3 (8.3%) M: 19 (70.4%) H + M: 1 (3.7%) Sparse: 3 (11.1%) −ve: 4 (14.8%) | DP: 25 (69.4%) FP: 11 (30.6%) DP: 17 (62.9%) FP: 9 (33.3%) −ve: 1 (3.7%) | PL: 19 (52.7%) CL: 10 (27.7%) Retained: 7 (19.6%) PL: 12 (44.4%) CL: 9 (33.3%) Retained: 6 (22.3%) | None None | 10.93 months (range: 0.2–82.6 months) |
| P value ODG vs Astro ODG vs GBM | – | 0.19 <0.001 | <0.001 0.17 | <0.001 0.20 | <0.001 0.02 | <0.05 0.045 | 0.15 0.007 | – | <0.001 |
The table shows the number of cases, their expression patterns, percentages, and statistical correlation. In addition, Sanger sequencing (SS) was performed in IDH-negative cases.
Abbreviations: CL = complete loss, DP = diffuse positive, H = homogenous, H + M = homogenous + mosaic, FP = focal positive, PL = partial loss, +ve = positive, −ve = negative.
Immunohistochemistry Was Performed For IDH, ATRX, P53, MIB, HIP 1 R, Vimentin, and H3K27me3 on Tumor Samples From Oligodendroglioma (Grades 2 and 3), Astrocytoma (Grades 2, 3, and 4), and Glioblastoma.
| Tumors . | n . | IDH R 132 H . | ATRX . | P53 . | Hip1R . | Vimentin . | H3K27Me3 . | 1p/19q co-deletion (FISH assay) . | Mean survival . |
|---|---|---|---|---|---|---|---|---|---|
| Oligodendroglioma (ODG) Validating Cohort | 102 24 | +ve (IHC): 97 (98.5%) +ve (SS): 5 (1.5%) +ve (IHC): 23 (95.8%) +ve (SS): 1 (4.2%) | Retained: 102 (100%) Retained: 24 (100%) | −ve: 102 (100%) −ve: 24 (100%) | H: 86 (84.3%) H + M: 16 (15.7%) H: 21 (87.5%) H + M: 3 (12.5%) | −ve: 93 (91.2%) FP: 9 (8.8%) −ve: 18 (75%) FP: 6 (25%) | CL: 102 (100%) CL: 23 (95.8%) PL: 1 (4.2%) | All cases All Cases | 21.23 months (range: 1.2–103.4 months) |
| Astrocytoma Validating Cohort | 44 22 | +ve (IHC): 40 (90.9%) +ve (SS): 4 (9.1%) +ve (IHC): 24 (100%) | Loss: 34 (77.3%) Retained: 10 (22.7%) Loss: 19 (86.4%) Retained: 3 (13.6%) | +ve: 33 (75%) −ve: 11 (25%) +ve: 21 (95.5%) −ve: 1 (4.5%) | M: 36 (81.8%) Sparse: 5 (11.4%) −ve: 3 (6.8%) M: 17 (77.2%) Sparse: 1 (4.5%) −ve: 4 (18.3%) | DP: 36 (81.8%) FP: 8 (18.2%) DP: 19 (86.4%) FP: 3 (13.6%) | CL: 33 (75%) PL: 9 (20.5%) Retained: 2 (4.5%) CL: 11 (50%) PL: 11 (50%) | None None | 18.25 months (range: 2–81.4 months) |
| GBM Validating Cohort | 36 27 | −ve: 36(100%) −ve: 27 (100%) | Retained: 36 (100%) Retained: 27 (100%) | +ve: 10 (27.7%)−ve: 26 (72.3%) +ve: 6 (22.2%) −ve: 21 (77.8%) | M: 28 (77.8%) H + M: 2 (5.6%) Sparse: 3 (8.3%) −ve: 3 (8.3%) M: 19 (70.4%) H + M: 1 (3.7%) Sparse: 3 (11.1%) −ve: 4 (14.8%) | DP: 25 (69.4%) FP: 11 (30.6%) DP: 17 (62.9%) FP: 9 (33.3%) −ve: 1 (3.7%) | PL: 19 (52.7%) CL: 10 (27.7%) Retained: 7 (19.6%) PL: 12 (44.4%) CL: 9 (33.3%) Retained: 6 (22.3%) | None None | 10.93 months (range: 0.2–82.6 months) |
| P value ODG vs Astro ODG vs GBM | – | 0.19 <0.001 | <0.001 0.17 | <0.001 0.20 | <0.001 0.02 | <0.05 0.045 | 0.15 0.007 | – | <0.001 |
| Tumors . | n . | IDH R 132 H . | ATRX . | P53 . | Hip1R . | Vimentin . | H3K27Me3 . | 1p/19q co-deletion (FISH assay) . | Mean survival . |
|---|---|---|---|---|---|---|---|---|---|
| Oligodendroglioma (ODG) Validating Cohort | 102 24 | +ve (IHC): 97 (98.5%) +ve (SS): 5 (1.5%) +ve (IHC): 23 (95.8%) +ve (SS): 1 (4.2%) | Retained: 102 (100%) Retained: 24 (100%) | −ve: 102 (100%) −ve: 24 (100%) | H: 86 (84.3%) H + M: 16 (15.7%) H: 21 (87.5%) H + M: 3 (12.5%) | −ve: 93 (91.2%) FP: 9 (8.8%) −ve: 18 (75%) FP: 6 (25%) | CL: 102 (100%) CL: 23 (95.8%) PL: 1 (4.2%) | All cases All Cases | 21.23 months (range: 1.2–103.4 months) |
| Astrocytoma Validating Cohort | 44 22 | +ve (IHC): 40 (90.9%) +ve (SS): 4 (9.1%) +ve (IHC): 24 (100%) | Loss: 34 (77.3%) Retained: 10 (22.7%) Loss: 19 (86.4%) Retained: 3 (13.6%) | +ve: 33 (75%) −ve: 11 (25%) +ve: 21 (95.5%) −ve: 1 (4.5%) | M: 36 (81.8%) Sparse: 5 (11.4%) −ve: 3 (6.8%) M: 17 (77.2%) Sparse: 1 (4.5%) −ve: 4 (18.3%) | DP: 36 (81.8%) FP: 8 (18.2%) DP: 19 (86.4%) FP: 3 (13.6%) | CL: 33 (75%) PL: 9 (20.5%) Retained: 2 (4.5%) CL: 11 (50%) PL: 11 (50%) | None None | 18.25 months (range: 2–81.4 months) |
| GBM Validating Cohort | 36 27 | −ve: 36(100%) −ve: 27 (100%) | Retained: 36 (100%) Retained: 27 (100%) | +ve: 10 (27.7%)−ve: 26 (72.3%) +ve: 6 (22.2%) −ve: 21 (77.8%) | M: 28 (77.8%) H + M: 2 (5.6%) Sparse: 3 (8.3%) −ve: 3 (8.3%) M: 19 (70.4%) H + M: 1 (3.7%) Sparse: 3 (11.1%) −ve: 4 (14.8%) | DP: 25 (69.4%) FP: 11 (30.6%) DP: 17 (62.9%) FP: 9 (33.3%) −ve: 1 (3.7%) | PL: 19 (52.7%) CL: 10 (27.7%) Retained: 7 (19.6%) PL: 12 (44.4%) CL: 9 (33.3%) Retained: 6 (22.3%) | None None | 10.93 months (range: 0.2–82.6 months) |
| P value ODG vs Astro ODG vs GBM | – | 0.19 <0.001 | <0.001 0.17 | <0.001 0.20 | <0.001 0.02 | <0.05 0.045 | 0.15 0.007 | – | <0.001 |
The table shows the number of cases, their expression patterns, percentages, and statistical correlation. In addition, Sanger sequencing (SS) was performed in IDH-negative cases.
Abbreviations: CL = complete loss, DP = diffuse positive, H = homogenous, H + M = homogenous + mosaic, FP = focal positive, PL = partial loss, +ve = positive, −ve = negative.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
